Foresight Diagnostics

Please join Stanford oncologist Ash Alizadeh's presentation at #ASH2024, where he will provide an in-depth overview of the #ALPHA3 trial conducted by Allogene Therapeutics. The ALPHA3 trial is exploring the use of novel “off-she-shelf” (or allogeneic) #CART for first-line consolidation therapy in large B-cell lymphoma (#LBCL). The trial utilizes an investigational ultra-sensitive minimal residual disease (#MRD) detection by Foresight CLARITY? to identify MRD-positive patients for enrollment. We will examine how integrating cutting-edge diagnostics with next-generation, off-the-shelf CAR T therapies could transform current treatment approaches, expedite CAR T access—especially in community settings—and ultimately enhance cure rates for LBCL. This event is open to all ASH registrants. Add to calendar -> https://t.ly/1z5sa

We are pleased to announce the presentation of multiple studies showcasing Foresight CLARITY? MRD at the upcoming #ASH24 annual meeting. The presentations span various #lymphoma types and treatment settings, demonstrating the broad applicability of Foresight CLARITY for monitoring treatment response and predicting patient outcomes. ? "These studies add to the growing body of evidence supporting ultra-sensitive #MRD testing as a critical tool in lymphoma care and drug development," said David Kurtz, MD, PhD, Chief Medical Officer and Head of Research. "We see in these studies that MRD measurement with Foresight CLARITY consistently enables earlier and more accurate treatment response assessment than conventional imaging-based methods. The ability to monitor disease status in real-time with ultra-sensitive MRD assays may help accelerate clinical trials and lead to more personalized decision-making for patient care.” We are grateful to our research collaborators at Stanford University School of Medicine, Washington University School of Medicine in St. Louis, Bristol Myers Squibb, AstraZeneca, Daiichi Sankyo US, and other leading institutions who are helping advance MRD testing in lymphoma care. Full press release: https://t.ly/OvOmc

Foresight is looking forward to being a part of next week's Liquid Biopsy Surveillance Summit in Boston. ? Our Chief Business Officer John Truesdell will lead a discussion on standardizing #ctDNA assays – a crucial step as #MRD endpoints become increasingly important to clinical trials.?? ? Join industry leaders Angela Silvestro, Lauren C. Leiman, and Jonathan Beer for insights on:? ? ?? Creating unified standards for ctDNA performance characteristics and testing? ?? Optimizing MRD endpoint integration? ?? Advancing clinical trial design? ? ? See you in Boston!? ? #LiquidBiopsy #ClinicalTrials #MRD #LBxSurveillance?

Join our webinar on November 20th at 1:00 pm ET (10:00 am PT) to explore the latest advancements in minimal residual disease (#MRD) detection and monitoring in early-stage #lungcancer and #breastcancer. Led by David Kurtz, Chief Medical Officer of Foresight Diagnostics, this session will feature data presentations from leading experts Luc Cabel from Memorial Sloan Kettering Cancer Center and Maximilian Diehn from Stanford Health. Registration and more information here -> https://t.ly/FGqzU

Join our webinar on November 20th at 1:00 pm ET (10:00 am PT) to explore the latest advancements in minimal residual disease (#MRD) detection and monitoring in early-stage #lungcancer and #breastcancer. Led by David Kurtz, Chief Medical Officer of Foresight Diagnostics, this session will feature data presentations from leading experts Luc Cabel from Memorial Sloan Kettering Cancer Center and Maximilian Diehn from Stanford Health. Registration and more information here -> https://t.ly/FGqzU

Our lab at Foresight Diagnostics was built to support MRD-driven clinical trials for our biopharma and academic research partners. In our new video, CEO Jake Chabon, COO Sandra Close, CMO David Kurtz, and CBO John Truesdell share their thoughts on the distinctive features of our lab capabilities, including: -> Delivering optimal turnaround times for clinical trial samples -> Maintaining rigorous and strict standards to quality management -> Providing high throughput capacity to enable support of global trials Watch video to learn more about our lab: https://lnkd.in/eV394W8r #MRD #ctdna #clinicaltrials #lymphoma

The core objective of #PrecisionMedicine is to deliver the right therapy to the right patient at the right time. While advancements in biomarker-based diagnostics and targeted therapies enhance our ability to identify "the right patient" and "the right drug," the question of timing remains crucial.? ?? In his presentation at the Advancing Precision Medicine conference, Mark Roschewski highlighted how ultra-sensitive #ctDNA detection can help pinpoint the time point to explore alternative treatment strategies that, ultimately, may help improve cure rates in first-line settings in #lymphoma.? ?? Strategies discussed include:? ?? Risk-adapted approaches -> investigating whether pre-treatment ctDNA levels impact response to 1L therapy Response-adapted approaches -> adjusting strategies based on mid-treatment ctDNA levels? Early-salvage approaches -> continuing treatment for patients with persistent MRD after first-line therapy to prevent relapse.? ?? By integrating precise, real-time tools like Foresight CLARITY at critical patient timepoints, we have the opportunity to rethink traditional treatment paradigms and enhance personalized clinical decision-making.?

#ForesightDx is looking forward to attending the Advancing Precision Medicine Conference in Philadelphia, PA, on November 1 and 2. Our research partner Dr. Mark Roschewski will discuss how advancements in ultra-sensitive #ctDNA technology may help evolve the precision medicine landscape in #lymphoma. Please join us for his presentation on November 1st at 4:45pm ET. Our Chief Business Officer John Truesdell and our Chief Operating and Compliance Officer Sandra Close will be attending. Interested in meeting? Schedule time to meet with our team here: Online: https://t.ly/FWBrA Email: [email protected] #PrecisionMedicine #AdvancingPrecisionMedicine #LiquidBiopsy #MRD #ForesightCLARITY #CancerResearch

#ForesightDx had an amazing time participating in The Susan G. Komen More Than Pink Walk this past weekend. Thank you to everyone who donated to our team. It was great to #connect to our #mission and see first hand the #impact our work could have on people affected by #cancer. See our most recent data in breast cancer here: https://t.ly/A2aQY #BreastCancerAwareness #MorethanPink #PinkWalk #PrecisionMedicine #LiquidBiopsy #MRD #ForesightCLARITY

Our partner Allogene Therapeutics will be speaking at the STAT Summit Conference on October 16th and 17th to discuss innovation in CAR T.?? ? For more information and to register: https://t.ly/lKza2 #MRD #ctDNA #PrecisionMedicine #LiquidBiopsy #CancerResearch #ForesightDx #CART